FindTrial
Sign In

Influenza vaccination in old age: Factors contributing to a good immune response

Influenza vaccination in old age: Immunological and biogerontological characterization of responders and non-responders - Influenza vaccination in old age

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-002147-10-AT
Enrollment
Unknown
Registered
2011-08-16
Start date
2011-09-21
Completion date
Unknown
Last updated
2015-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This study will analyze cellular and humoral immune responses after seasonal vaccination against influenza. Healthy adults are vaccinated with a licensed trivalent inactivated vaccine without adjuvant. The vaccine is licensed for all age groups studied in this study. MedDRA version: 14.0 Level: LLT Classification code 10016794 Term: Flu vaccination System Organ Class: 10042613 - Surgical and medical procedures MedDRA version: 14.0 Level: LLT Classification code 10046859 Term: Vaccination Syste

Interventions

Trade Name: Preflucel Product Name: Prefluvac Pharmaceutical Form: Solution for injection

Sponsors

Institute for Biomedical Aging Research
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: signed informed consent form participant of the former MARK-AGE study no previous influenza vaccination in the 2011/2012 season Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 150 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 150

Exclusion criteria

Exclusion criteria: acute illness chronic inflammatory disease (e.g. inflammatory bowl disease, Multiple Sclerosis) chronic infection with HBV, HCV or HIV transplant recipients persons who have recieved chemotherapy in the past persons under immunosuppressive therapy pregnant women participation in another clinical trial during the study

Design outcomes

Primary

MeasureTime frame
Main Objective: To analyze the humoral and cellular immune response after influenza vaccination in different age groups (>35 years). Determination of influence of age on vaccine-induced immune response and analysis of interaction between cellular and humoral responses.;Secondary Objective: Identification of biological parameters for prediction of vaccination success. Immunological and biogerontological characterisation of responders and non-responders.;Primary end point(s): Quantification of vaccine-induced immune responses 4 weeks after vaccination—

Countries

Austria

Contacts

Public ContactBeatrix Grubeck-Loebenstein

Institute for Biomedical Aging Research

beatrix.grubeck@oeaw.ac.at4351258391910

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026